Comparative Pharmacology
Head-to-head clinical analysis: COMTAN versus TOLCAPONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMTAN versus TOLCAPONE.
COMTAN vs TOLCAPONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective and reversible inhibitor of catechol-O-methyltransferase (COMT), which inhibits the metabolism of levodopa to 3-O-methyldopa, thereby increasing the plasma half-life and bioavailability of levodopa in the brain.
Tolcapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). It inhibits both peripheral and central COMT activity, thereby reducing the metabolism of levodopa to 3-O-methyldopa and increasing the bioavailability and duration of action of levodopa in the brain.
200 mg orally once daily, increased to 200 mg three times daily as tolerated, with each dose of levodopa/carbidopa; maximum 200 mg per dose.
100 mg orally three times daily. The first dose of the day should be taken together with the first daily dose of levodopa/carbidopa.
None Documented
None Documented
Clinical Note
moderateTolcapone + Torasemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide."
Clinical Note
moderateTolcapone + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Etacrynic acid."
Clinical Note
moderateTolcapone + Furosemide
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Furosemide."
Clinical Note
moderateTolcapone + Bumetanide
Terminal elimination half-life is approximately 0.4 to 0.7 hours (mean 0.7 hours) in plasma, but the pharmacodynamic half-life (COMT inhibition) is longer, about 2-4 hours, supporting thrice-daily dosing.
Terminal elimination half-life is 2–3 hours in healthy subjects; in patients with hepatic impairment, it may be prolonged up to 8–10 hours, necessitating dose reduction.
Primarily fecal (90%) as unchanged drug; renal excretion accounts for approximately 10%, mostly as glucuronide conjugates.
Primarily hepatic metabolism (glucuronidation and methylation), with minimal renal excretion of unchanged drug. Fecal excretion accounts for approximately 40% of the dose, with 14% excreted in urine as glucuronide conjugates. Less than 1% of the dose is recovered as unchanged tolcapone in urine.
Category C
Category A/B
COMT Inhibitor
COMT Inhibitor
"The risk or severity of adverse effects can be increased when Tolcapone is combined with Bumetanide."